CMPX Compass Therapeutics Forecast, Technical & Fundamental Analysis
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases... Show more
CMPX is expected to report earnings to rise 10.70% to -11 cents per share on August 05
Q2'26
Est.
$-0.11
Q1'26
Est.
$-0.10
Q4'25
Beat
by $0.01
Q3'25
Beat
by $0.06
Q2'25
Missed
by $0.02
The last earnings report on May 05 showed earnings per share of -10 cents, meeting the estimate of -10 cents. With 825.62K shares outstanding, the current market capitalization sits at 372.78M.
A.I.dvisor indicates that over the last year, CMPX has been loosely correlated with VCYT. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CMPX jumps, then VCYT could also see price increases.
CMPX's Stochastic Oscillator stays in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for CMPX crossed bullishly above the 50-day moving average on July 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 191 cases where CMPX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CMPX as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CMPX turned negative on July 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
CMPX moved below its 50-day moving average on July 24, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMPX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CMPX broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.999) is normal, around the industry mean (19.191). P/E Ratio (0.000) is within average values for comparable stocks, (38.162). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.511). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (555.556) is also within normal values, averaging (394.782).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CMPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
